| Home |
Molecular Staging of Cancer (Recent Results in Cancer Research v. 162)
228 pages - hardback
Springer-Verlag Berlin and Heidelberg GmbH & Co. K - (isbn 3-540-43469-0)
Mar. 2002
|
||||||||
|
|
||||||||
|
|
Molecular Staging of Cancer (Recent Results in Cancer Research v. 162) 228 pages - hardback Springer-Verlag Berlin and Heidelberg GmbH & Co. K - (isbn 3-540-43469-0) Mar. 2002 |
|
||||||
| Price: |
131,67 EUR
|
|||||||
| Editor: |
Allgayer, H. / Heiss, M.M. / Schildberg, F.W. (all of Ludwig-Maximilians-Universitat Munchen, Germany)
|
|||||||
| Description: |
An
explosion of information has occurred since scientists began to define
the molecular events that describe the malignant transformation and
progression of cells and their development towards a life-threatening
metastatic disease. The First International Congress on Molecular
Staging of Cancer, held in Munich in December 2001, aimed to establish
an international platform of exchange among molecular biologists, cell
biologists, tumor immunologists, and clinical and surgical oncologists.
This network approach should be fruitful for both clinicians and
researchers. The highlighted topics included tumor-associated
proteolysis, minimal residual disease, new approaches for molecular
diagnosis and targeting, and the first molecular staging models. One
session focused on technology transfer, opening up a new field of
funding for innovative concepts. Finally, the impact of molecular
staging on clinical strategies was discussed.
|
|||||||
| Contents List: |
From
the contents: The urokinase receptor (uPAR, CD87) as a target for tumor
therapy; Molecular regulation of urokinase receptor (u-PAR) gene
expression as one potential concept for molecular staging and therapy;
Stromal cell involvement in cancer; Inhibition of the tumor-associated
urokinase-type plasminogen activation system: effects of high level
synthesis of soluble urokinase receptor in ovarian and breast cancer
cells in vitro and in vivo; Molecular mechanisms of carcinogenesis in
gastric cancer; Clinical implications of molecular diagnosis in HNPCC;
Minimal residual disease in gastric cancer; Minimal residual disease in
breast cancer and gynecological malignancies; Clinical implications of
the EGF-receptor/ligand system for tumor progression and survival in
gastrointestinal carcinomas: evidence for new therapeutic options;
Minimal residual disease in the bone marrow and peripheral blood of
patients with metastatic breast cancer; Estrogen receptor (ER)
expression profile of disseminated epithelial tumor cells in the bone
marrow of breast cancer patients; Detection of circulating tumor cells
in blood using an optimized density gradient centrifugation;
Antitumoral and antimetastatic effects of continuous particle mediated
cytokine gene therapy; Genetic subtyping of renal cell carcinoma by
comparative genomic hybridization; Telomere length and hTERT expression
in patients with colorectal carcinoma; Evaluation of the level of bFGF,
VEGF, sICAM-1, sVCAM-1 in the serum of patients with thyroid cancer.
|
|||||||
| Illustrations etc.: | 35 illustrations | |||||||
| Weight: | 454 g | |||||||
| Dimensions: | 230 | |||||||
| Publisher: | Springer-Verlag Berlin and Heidelberg GmbH & Co. KG | |||||||
| Springer-Verlag | ||||||||